Skip to content
DataLookout
Menu

TARBELA-PDNCT07781644

Study to Test Effects and Safety of RO7568282 in Early Parkinson's Disease

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Start date changed from estimate of Nov 10, 2026 to Nov 11, 2026
    • Study sites: 4 to 6
  2. Notable Phase changed: Phase 1/2 → Phase 2
    • Recruitment opened
    • Start date pushed from Sep 30, 2026 to Nov 10, 2026
    • Trial sites expanded: 0 → 4 locations
  3. Minor Study sites: 0 to 2
  4. Notable Eligibility criteria expanded, about 12 words
    • Secondary endpoints: details revised at 1 of 5 entries
  5. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Time to a Confirmed Motor Progression Event From the Randomization Date, as Measured by the MDS-UPDRS Part III Score
Timeframe: Up to at least Week 104

Secondary (5)

Change in Motor Signs From Baseline at Week 104, as Measured by the MDS-UPDRS Part III Score
Time to Worsening of Participants' Motor Function, as Reported by the Participant in the Presence of a Confirmed Motor Progression Event
Incidence of Adverse Events (AEs)
Change From Baseline in Columbia-suicide Severity Rating Scale (C-SSRS)
Plasma Concentrations of RO7568282

Arms and interventions

RO7568282 High DoseExperimental

RO7568282 will be administered as per the schedule specified in the protocol.

RO7568282 Low DoseExperimental

RO7568282 will be administered as per the schedule specified in the protocol.

PlaceboPlacebo comparator

Placebo will be administered as per the schedule specified in the protocol.

Drugs: RO7568282, Placebo

Sites

6 sites in 5 countries

United Kingdom 2, China 1, Ireland 1, Poland 1, United States 1